Effects of physical activity and exercise on glycaemic control in cystic fibrosis

Royal Prince Alfred Hospital0 个研究点目标入组 56 人开始时间: 2022年3月4日最近更新: 2024年6月10日

适应症

试验速览

暂无简介。

•a.RPAH CF clinic patients, aged 17 years and over, who are clinically stable.
•b. CF Patients with Cystic fibrosis related diabetes( CFRD) (n=15), impaired fasting glucose tolerance (n=15) and those with normal glycaemic control (n=15), according to their most recent oral glucose tolerance test (within 3 years, where applicable).
•c. Clinically-stable at time of data collection, as assessed by the patient’s treating respiratory physician, including no non-routine antibiotics in the previous 14 days.
•d. Provides informed consent. e. Eligible for Elexacaftor/Tezacaftor/ Ivacaftor (TrikaftaTM) · Healthy control participants:
•. Healthy clinically stable participants, aged 17 years and over.
•No history of cardiovascular, neuromuscular, endocrine, respiratory disease

•a. Unable to perform moderate intensity exercise or use continuous glucose monitoring device. b. Colonisation with Tier 3 organisms (Burkholderia cepacia, non-tuberculous mycobacteria) c. Previous lung transplant. d. Pregnant or lactating females. e. Known hypoglycaemia unawareness f. Mobile phone not compatible with the continuous glucose monitoring devic

发起方